Literature DB >> 28844793

Utilization and Outcomes of Radical Cystectomy for High-grade Non-muscle-invasive Bladder Cancer in Elderly Patients.

William P Parker1, Woodson Smelser2, Eugene K Lee2, Elizabeth B Habermann3, Prabin Thapa3, Harras B Zaid4, Igor Frank4, Tomas L Griebling5, Matthew K Tollefson4, R Houston Thompson4, Jeffrey M Holzbeierlein2, R Jeffrey Karnes4, Stephen A Boorjian6.   

Abstract

BACKGROUND: Radical cystectomy (RC) represents a treatment option for patients with high-grade non-muscle-invasive bladder cancer (HG-NMIBC); however, perioperative morbidity is not insignificant, particularly in elderly patients. We sought to evaluate the associations of age with utilization and outcomes of RC for HG-NMIBC. PATIENTS AND METHODS: Patients with HG-NMIBC diagnosed between 2004 and 2013 were identified in the National Cancer Database and stratified by age: ≤ 60, 61-70, 71-80, and > 80 years. Association between age and treatment with RC was assessed by multivariable logistic regression. Associations between age and overall survival were assessed using the Kaplan-Meier method. A multi-institutional analysis was performed to evaluate the associations of age with perioperative outcomes and survival among patients managed with RC for HG-NMIBC.
RESULTS: On multivariable analysis, age was associated with RC utilization, with the lowest usage in patients > 80 years (2.1%; P < .01). Upstaging at RC occurred in 40% of patients with HG-NMIBC, and no association of age with upstaging risk was noted. Significantly inferior overall survival was observed in the patients who were upstaged across age strata (all P < .01). In the multi-institutional cohort, age was not associated with risks of upstaging, receipt of transfusion, 30-/90-day complications, or recurrence-free or cancer-specific survival (all P > .05), whereas upstaging was associated with inferior recurrence-free and cancer-specific survival regardless of age.
CONCLUSION: RC for HG-NMIBC is used less frequently in older adults, despite similar risks of pathologic upstaging. As upstaging is associated with inferior survival regardless of age, these data suggest that elderly patients with HG-NMIBC may be at risk for undertreatment.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complications; Outcomes; Practice patterns; Upstaging; Utilization

Year:  2017        PMID: 28844793     DOI: 10.1016/j.clgc.2017.07.011

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN: 1558-7673            Impact factor:   2.872


  5 in total

1.  The prognostic impact of hexaminolevulinate-based bladder tumor resection in patients with primary non-muscle invasive bladder cancer treated with radical cystectomy.

Authors:  Markus Renninger; Omar Fahmy; Tina Schubert; Manuel Alexander Schmid; Fahmy Hassan; Arnulf Stenzl; Georgios Gakis
Journal:  World J Urol       Date:  2019-04-27       Impact factor: 4.226

Review 2.  Defining Undertreatment and Overtreatment in Older Adults With Cancer: A Scoping Literature Review.

Authors:  Clark DuMontier; Kah Poh Loh; Paul A Bain; Rebecca A Silliman; Tammy Hshieh; Gregory A Abel; Benjamin Djulbegovic; Jane A Driver; William Dale
Journal:  J Clin Oncol       Date:  2020-04-06       Impact factor: 50.717

3.  Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer.

Authors:  Iris S G Brummelhuis; Yvonne Wimper; Hilde G J M Witjes-van Os; Tom J H Arends; Antoine G van der Heijden; J Alfred Witjes
Journal:  Cancers (Basel)       Date:  2021-01-20       Impact factor: 6.639

4.  The impact of different adjuvant intravesical therapy methods on tumor biology in patients with high-risk non-muscle-invasive bladder cancer.

Authors:  Fedir Kostyev; Oleksandr Bondar; Roman Chystiakov; Viktoria Lysenko; Oleksiy Stavnychyi; Valeria Varbanets
Journal:  Cent European J Urol       Date:  2021-10-22

5.  Effectiveness of Early Radical Cystectomy for High-Risk Non-Muscle Invasive Bladder Cancer.

Authors:  Elliott Diamant; Mathieu Roumiguié; Alexandre Ingels; Jérôme Parra; Dimitri Vordos; Anne-Sophie Bajeot; Emmanuel Chartier-Kastler; Michel Soulié; Alexandre de la Taille; Morgan Rouprêt; Thomas Seisen
Journal:  Cancers (Basel)       Date:  2022-08-04       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.